Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy.
Intravesical chemotherapy using mitomycin C in patients with superficial bladder cancer after transurethral resection (TUR) has proved to be highly effective in preventing tumor recurrences and/or progression. No consensus has been reached on the appropriate dose and treatment schedule. This and other variable factors such as different criteria for entry and follow-up in the reported studies so far make it impossible to compare the results. There are indications that long-term mitomycin C instillation therapy improves recurrence rate, progression rate, and survival. Considering prognostic factors in patients with superficial bladder tumors, it is justified and necessary to investigate this regimen in future protocols.
D000283:Administration, Intravesical; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D008937:Mitomycins; D016685:Mitomycin